Brad Stanfield on Fisetin
4 episodes · 6 references · 2022–2025
- Stanfield stopped taking fisetin after the Interventions Testing Program showed no lifespan or healthspan benefits in mice - Acknowledges early preclinical data showed fisetin was the most potent senolytic out of 10 molecules tested, but considers this insufficient - No dosing guidance or personal consumption details discussed; advises others to stop spending money on fisetin
Benefits
- Fisetin ranked as the most potent senolytic out of 10 molecules tested in preclinical research - Extended both median and maximum lifespan in inbred mice in early studies - Stanfield notes these promising early results were not replicated in the larger Interventions Testing Program
Cautions
- The Interventions Testing Program found no lifespan extension or healthspan benefits from fisetin in mice - Stanfield advises stopping fisetin supplementation, citing lack of supporting mouse research and absence of human randomized clinical trials - Concluded that senolytic preclinical work has not yet been validated sufficiently to justify supplementation
“I used to take both quercetin and fisetin five days in a row each month and this was for the senolytic effect. I've stopped taking fisetin.”
Stop Quercetin Supplements (New Study)
$0.18/ct
$16.64 total
$0.37/ct
$21.95 total
$0.38/ct
$22.95 total
$0.43/ct
$25.99 total
$0.74/ct
$44.41 total
$0.81/ct
$24.31 total